Study #2023-0580
A phase 1, first-in-human, open-label, multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
JZP898, Pembrolizumab
Description
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Metastatic Solid Tumor
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.